Edition:
United States

Alere Inc (ALR.N)

ALR.N on New York Stock Exchange

39.95USD
24 Feb 2017
Change (% chg)

$-0.42 (-1.04%)
Prev Close
$40.37
Open
$40.29
Day's High
$40.37
Day's Low
$39.93
Volume
66,162
Avg. Vol
130,205
52-wk High
$54.00
52-wk Low
$31.47

Latest Key Developments (Source: Significant Developments)

European Commission clears Abbott acquisition of Alere
Wednesday, 25 Jan 2017 11:00am EST 

Alere Inc : European Commission clears Abbott acquisition of Alere .Alere inc - "We remain highly confident that merger will close according to terms of agreement" with Abbott.  Full Article

Alere provides update on Arriva Medical
Wednesday, 28 Dec 2016 05:03pm EST 

Alere Inc : Alere provides update on Arriva Medical . Arriva has filed an appeal with administrative law judge (ALJ) at CMS seeking to reinstate Arriva's billing status . Alere Inc says expects a decision on its motions to enjoin on or about January 5, 2017 . Provided an update on decision by centers for Medicare & Medicaid services to revoke Arriva Medical's medicare billing privileges .Alere Inc- Arriva filed complaint seeking to compel CMS to stay process regarding competitive bidding contract termination while ALJ appeal is ongoing.  Full Article

Alere comments on Abbott's lawsuit
Wednesday, 7 Dec 2016 12:59pm EST 

Alere Inc : Alere issues statement regarding Abbott lawsuit . "Abbott's lawsuit is entirely without merit" . "Alere has fully complied with its contractual obligations under merger agreement" . Paul, Weiss, Rifkind, Wharton & Garrison and Cravath, Swaine & Moore LLP are serving as legal counsel to alere . Abbott well knows, none of issues it has raised provides it with any grounds to avoid closing merger . Alere will take all actions "to compel Abbott to complete transaction in accordance with its terms" ."Is highly confident that merger will be completed in accordance with terms set forth in merger agreement".  Full Article

Abbott says seeks to terminate Alere acquisition
Wednesday, 7 Dec 2016 11:14am EST 

Abbott Laboratories : Abbott seeks to terminate Alere acquisition . "Alere is no longer company Abbott agreed to buy 10 months ago" . In 10 months following Jan. 30, 2016, signing of agreement, Alere has "suffered a series of damaging business developments" . "We have attempted to secure details and information to assess these issues for months, and Alere has blocked every attempt" . Abbott filed its complaint seeking termination in delaware court of Chancery ."Damage to Alere's business can only be result of a systemic failure of internal controls".  Full Article

FDA concludes Xarelto clinical trial results not affected by Alere's INRatio
Tuesday, 11 Oct 2016 12:41pm EDT 

U.S. FDA: Analyses conclude that Xarelto clinical trial results were not affected by Alere's faulty monitoring device INRatio .FDA concludes blood thinner drug Xarelto is a safe and effective alternative to warfarin in patients with atrial fibrillation.  Full Article

Alere Q2 loss per share $0.46 from continuing operations
Tuesday, 6 Sep 2016 07:00am EDT 

Alere Says With Filing Of Q2 2016 Form 10 : Alere reports second quarter 2016 financial results . Q2 revenue $611 million versus I/B/E/S view $607.4 million . Q2 loss per share $0.46 from continuing operations . Q2 earnings per share view $0.58 -- Thomson Reuters I/B/E/S .Alere says with filing of Q2 2016 form 10-Q now current in financial filings and are on track to report our Q3 2016 results within normal time frame.  Full Article

Abbott Laboratories says "Alere’s lawsuit is without merit"
Friday, 26 Aug 2016 12:26pm EDT 

Abbott Laboratories : Abbott Laboratories says "Alere’s lawsuit is without merit" . Compliant with obligations under merger agreement with Alere . "continues to work toward regulatory approvals despite Alere’s nearly six month delay in filing its 2015 10-K" ((Bangalore.newsroom@thomsonreuters.com ;)).  Full Article

Alere says filed a complaint against Abbott on Aug. 25
Friday, 26 Aug 2016 11:00am EDT 

Alere Inc : Alere issues statement . "on August 25, 2016, Alere filed a complaint against Abbott in Delaware Chancery court" . Says expect redacted version of complaint to be publicly available next week . Expect redacted version of complaint to be publicly available next week .Alere will "compel" Abbott to complete transaction in accordance with its terms.  Full Article

Alere gets FDA clearance for its RSV rapid molecular test
Friday, 19 Aug 2016 07:00am EDT 

Alere Inc : Alere receives FDA clearance for Alere™ I RSV rapid molecular test . Alere will shortly submit an application for clia waiver of Alere I RSV test .Alere I testing applications have previously been clia-waived for Influenza a & b and strep a.  Full Article

Alere entered into a second amendment to secured credit agreement
Thursday, 18 Aug 2016 05:13pm EDT 

Alere Inc : On August 18 entered into a second amendment to secured credit agreement .Second amendment extends the deadline for delivery of the Q2 financial reports to September 13, 2016 - sec filing.  Full Article

More From Around the Web

Photo

Abbott pauses on deals, to focus on St. Jude integration

Abbott Laboratories said it planned to focus on slashing its debt and integrating its $25 billion acquisition of St. Jude Medical in 2017, in a break from the hectic pace of dealmaking last year